semaglutide injection success stories JOURNEY RECAP // How I lost 30 lbs in 3 months, milestones, challenges + sustainability Not my most flattering photos.

The trial was designed to assess the efficacy and safety of semaglutide, a once-weekly subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in preventing major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes, in individuals with type 2 diabetes and chronic kidney disease

Semaglutide should not be used in combination with other GLP-1 receptor agonists

The website and its authors shall not be liable for any damages, including without limitation, indirect or consequential damages, arising from the use or inability to use the content on this blog

The timeline varies based on your starting dose, dose escalation schedule, and individual metabolic response